Clinical Trials Browser

Terminated × Castleman Disease × Clear all

NCT01552434 2026-05-15

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

BreastCNSGenitourinaryHead & NeckLymphoidMyeloidSarcoma

Breast Neoplasms, Carcinoma, Transitional Cell, Endocrine Gland Neoplasms, Castleman Disease, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms, Pharyngeal Neoplasms, Recurrence, Sarcoma, Soft Tissue Neoplasms, Thyroid Neoplasms, Urologic Neoplasms, Neurofibromatosis 2, Lymphangioleiomyomatosis, Neoplasms, Mesothelial, Erdheim-Chester Disease

NCT02080416 2016-06-10

Nelfinavir for the Treatment of Gammaherpesvirus-Related Tumors

Phase EARLY_PHASE1 Terminated

1 enrolled

GastrointestinalHead & NeckLymphoidSarcoma

Castleman Disease, Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Nasopharyngeal Neoplasms, Neoplasms, Sarcoma, Sarcoma, Kaposi, Stomach Neoplasms

NCT00127569 2007-01-12

Rituximab in the Treatment of HIV Associated Multicentric Castleman Disease Dependent on Chemotherapy

Phase 2 Terminated

25 enrolled

LymphoidSarcoma

Castleman Disease, Sarcoma, Kaposi, HIV Infections